JAMA Author Interviews

Long COVID is now defined as a heterogeneous, infection-associated chronic condition present for at least 3 months after SARS-CoV-2 infection. Author Leora Horwitz, MD, MHS, of NYU Grossman School of Medicine joins JAMA Executive Editor Gregory Curfman, MD, to discuss the JAMA article "2024 Update of the RECOVER-Adult Long COVID Research Index." Related Content: 2024 Update of the RECOVER-Adult Long COVID Research Index Characterizing Long COVID in Children and Adolescents

Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial." Related Content: Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer

New antiretroviral drugs and formulations continue to become available for the prevention and management of HIV infection. Author Rajesh T. Gandhi, MD, joins JAMA Deputy Editor Preeti Malani, MD, MSJ, to discuss these new approaches for HIV. Related Content: Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society–USA Panel Advances in Treatment and Prevention of HIV

A new JAMA study examines the association between severe maternal morbidity in a first birth and the probability of a subsequent birth. Authors Neda Razaz, PhD, and Eleni Tsamantioti, MD, MMedSc, both from the Karolinska Institute in Sweden, discuss this and more with JAMA Associate Editor Melissa A. Simon, MD, MPH. Related Content: Association of Severe Maternal Morbidity With Subsequent Birth Severe Maternal Morbidity and Subsequent Birth—Understanding and Informing a Woman’s Choice

Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic’s Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content: Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)

Preterm birth is the greatest cause of neonatal mortality and morbidity, with infants born extremely preterm at highest risk. Author Brett J. Manley, PhD, the Royal Women’s Hospital, Melbourne, Australia, discusses a new study of the effect of intratracheal corticosteroid administration on survival free of bronchopulmonary dysplasia in preterm infants, with JAMA Deputy Editor Tracy A. Lieu, MD, MPH. Related Content: Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants

Preventing obesity in early childhood is challenging for clinicians and families. Authors Eliana M. Perrin, MD, MPH, of Johns Hopkins University, and William J. Heerman, MD, MPH, of Vanderbilt University, join JAMA Deputy Editor Tracy Lieu, MD, to discuss "A Digital Health Behavior Intervention to Prevent Childhood Obesity: The Greenlight Plus Randomized Clinical Trial." Related Content: A Digital Health Behavior Intervention to Prevent Childhood Obesity

A new study published in JAMA found that drug-related supply chain issue reports were 40% less likely to result in meaningful drug shortages in Canada compared with the US. Authors Kate Suda, PharmD, MS, of University of Pittsburgh School of Medicine, and Mina Tadrous, PharmD, PhD, of University of Toronto, discuss this and more with JAMA Deputy Editor Joseph S. Ross, MD, MHS. Related Content: Differences in Drug Shortages in the US and Canada Understanding Drug Supply Shortages in the US and Canada

In the US, childbirth typically occurs in hospitals or accredited birth centers. President of the American College of Obstetricians and Gynecologists Stella Marie Dantas, MD, speaks with JAMA Deputy Editor Linda Brubaker, MD, MS, about newly proposed advanced birth centers that would permit higher-risk births, with concerns for patient safety and rural obstetric care access. Related Content: Advanced Birth Centers and the Effect on Maternity Care

The Declaration of Helsinki originated in 1964, developed by the World Medical Association (WMA). Process Chair Jack S. Resneck Jr, MD, discusses the 2024 updates to the Declaration of Helsinki with JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS. Related Content: Revisions to the Declaration of Helsinki on Its 60th Anniversary World Medical Association Declaration of Helsinki Making the Ethical Oversight of All Clinical Trials Fit for Purpose The Revised Declaration of Helsinki—Considerations for the Future of Artificial Intelligence in Health and Medical Research Revisiting the Declaration of Helsinki—A Patient-Centered Perspective Future-Proofing Research Ethics—Key Revisions of the Declaration of Helsinki 2024 The Revision of the Declaration of Helsinki Viewed From the Americas—Paving the Way to Better Research Declaration of Helsinki—Revisions for the 21st Century Facilitating Efficient and Ethical Trials at the Intersection of Research and Clinical Care The 2024 Revision to the Declaration of Helsinki